Full-year 2025 results

2025 Sales

$94.2B

Worldwide increased ▲ **6.0%**

Excluding the impact of translational currency

Stelara impacted results by ~(620) basis points

Worldwide increased ▲ **5.3%**[1]

Diluted earnings per share (EPS)

$11.03


Includes the reversal of special charges

Adjusted diluted earnings per share[1]

$10.79

Worldwide increased ▲ **8.1%**





Joaquin Duato
Chairman & Chief Executive Officer
Johnson & Johnson

"2025 was a catapult year for Johnson & Johnson, fueled by the strongest portfolio and pipeline in our history. Last year kicked off a new era of accelerated growth, driven by medical innovation that is transforming lives in our six key businesses: Oncology, Immunology, Neuroscience, Cardiovascular, Surgery, and Vision. In each of these important areas, our leadership is expanding driven by game-changing science and technology."

$60.4 billion Worldwide Innovative Medicine sales

Innovative Medicine worldwide reported sales increased 6.0% or 5.3% operationally[2]. Stelara impacted results[2] by ~(1,040) basis points. Primary operational drivers:

DARZALEX® (daratumumab) injection for intravenous infusion 100 mg/5 mL, 400 mg/20 mL

Tremfya® (guselkumab)

CARVYKTI® (ciltacabtagene autoleucel) Suspension for IV Infusion

CAPLYTA® (lumateperone) capsules 42 mg

Spravato™ (esketamine) CIII nasal spray

Erleada® (apalutamide) 60 mg tablets 240 mg tablet

Simponi® golimumab

RYBREVANT® (amivantamab-vmjw) Injection for IV Use | 350 mg/7 mL (50 mg/mL) + LAZCLUZE™ (lazertinib)

$33.8 billion Worldwide MedTech sales

MedTech worldwide reported sales increased 6.1% or 5.4% operationally[2] Primary operational drivers:

- Shockwave
- Electrophysiology
- Abiomed
- Wound Closure
- Surgical Vision
- Contact Lenses
- Biosurgery

For full financial data, non-GAAP reconciliations and cautionary statements, please refer to Johnson & Johnson's earnings release issued on January 21, 2026 available at https://www.investor.jnj.com/financials/quarterly-results/default.aspx

[1] Non-GAAP financial measure; non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

[2] Non-GAAP measure; excludes the impact of translational currency.

Note: Values may be rounded

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events. For important information about the risks and uncertainties that could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements, review the "Note to Investors Concerning Forward-Looking Statements" included in the Johnson & Johnson earnings release issued on January 21, 2026 as well as the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson&Johnson